DEVELOPMENT
DEVELOPMENT
TissueGen is advancing toward clinical development a pipeline of novel, extended release
TissueGen is advancing toward clinical development a pipeline of novel, extended release
formulations of generic drugs for the treatment of eye, nerve, and joint injuries and diseases.
formulations of generic drugs for the treatment of eye, nerve, and joint injuries and diseases.
Our proprietary TGen technology allows us to formulate a broad range of therapeutics – from sensitive antibodies and growth factors to molecules typically incompatible with solvents used to formulate polymeric delivery systems – into extended release formulations precisely tailored to meet even the most demanding delivery profiles. Using formats from microspheres to fibers, we can design the right extended release system for nearly any compartment in the body, from eyes and nerve sheaths to joints and skin.
TissueGen is advancing a pipeline of novel, extended release formulations of generic drugs for the treatment of eye, nerve, and joint injuries and diseases toward clinical development.
Stay tuned for updates.
APPLICATIONS
TissueGen is advancing a pipeline of novel, extended release formulations of generic drugs
for the treatment of eye, nerve, and joint injuries and diseases toward clinical development.
Stay tuned for updates.
ADVANCED
DRUG DELIVERY
Our proprietary TGEM
technology allows us to formulate a broad range of
therapeutics – from sensitive antibodies and growth factors to
molecules typically incompatible with solvents used to formulate
polymeric delivery systems – into extended release formulations
precisely tailored to meet even the most demanding delivery
profiles. Using formats from microspheres to fibers, we can
design the right extended release system for nearly any
compartment in the body, from eyes and nerve
sheaths to joints and skin.
DEVELOPMENT
NERVE
REGENERATION
Our proprietary fibers can be tailored to deliver sensitive growth factors along a precise gradient for an extended period of time. We are developing applications of this technology for the repair of severed peripheral nerves without the need for harvesting nerves from elsewhere in the patient’s body.
NERVE
REGENERATION
Our proprietary fibers can be
tailored to deliver sensitive growth factors
along a precise gradient for an extended period
of time. We are developing applications of this technology
for the repair of severed peripheral nerves without
the need for harvesting nerves from elsewhere
in the patient’s body.
Our strong, pliable fibers can be woven, knitted, or braided to create biomimetic three- dimensional structures with unrivaled drug delivery capabilities for accelerating healing of repaired hernias and soft tissue injuries involving ligaments and tendons.
TISSUE
ENGINEERING
Our strong, pliable fibers can be
woven, knitted, or braided to create
biomimetic three-dimensional structures with unrivaled
drug delivery capabilities for accelerating healing of repaired
hernias and soft tissue injuries involving
ligaments and tendons.
PATENTS
COUNTRIES
Below you will find a list of our issued patents and pending applications.
DRUG RELEASING BIODEGRADABLE
FIBER IMPLANT:
CANADA
2379909 - Granted
CHINA
00814022.7 - Granted
EUROPEAN PATENT CONVENTION
00952592.4 - Pending
DRUG RELEASING BIODEGRADABLE
FIBER FOR THE DELIVERY OF THERAPEUTICS:
AUSTRALIA
2004237770 - Granted
CANADA
2523620 - Granted
CHINA
200480018348.8- Granted
EUROPE
1620038 - Granted
FRANCE
1620038 - Granted
GERMANY
1620038 - Granted
GREAT BRITAIN
1620038 - Granted
ITALY
1620038 - Granted
JAPAN
2006-513446 - Granted
2012-046180 - Granted
SPAIN
1620038 - Granted
USA
2006-513446 - Granted
2012-046180 - Granted
CHEMICAL GRADIENTS:
AUSTRALIA
2014219149 - Granted
CANADA
2,901,919 - Pending
CHINA
201480017217.1 - Pending
201710861068.2 - Pending
EUROPEAN PATENT CONVENTION
14709037.7 - Pending
JAPAN
2015-558197 - Pending
USA
14/768,820 - Pending
SELF EXPANDING MEDICAL DEVICE:
AUSTRALIA
2009283913 - Granted
CANADA
2734493 - Granted
CHINA
ZL200980137732- Granted
EUROPEAN PATENT CONVENTION
2326292 - Granted
FRANCE
2326292 - Granted
GERMANY
2326292 - Granted
GREAT BRITAIN
2326292 - Granted
INDIA
1933/DELNP/2011 - Pending
ITALY
502016000124521 - Granted
JAPAN
5713900 - Granted
SPAIN
2326292 - Granted
USA
8,672,996 - Granted
DRUG ELUTING SELF RETAIN SUTURES
AND METHODS RELATING THERETO:
AUSTRALIA
2011323299 - Granted
BRAZIL
BR112013011090-2 - Pending
CANADA
2816326 - Pending
CHINA
201180063975.3- Pending
EUROPEAN PATENT CONVENTION
11838842.0 - Pending
INDIA
3929/DELNP/2013 - Pending
JAPAN
2013-537843 - Pending
KOREA
2013/7014209 - Pending
MEXICO
MX/A/2013/005072 - Pending
NEW ZEALAND
610341 - Pending
RUSSIA
2013125475- Granted
SOUTH AFRICA
2013/04011 - Pending
USA
13/883066 - Pending
DEVICE FOR INDUCTION OF CELLULAR ACTIVITY:
AUSTRALIA
2015346044 - Pending
CANADA
2967650 - Pending
CHINA
201580073483.0 - Pending
EUROPEAN PATENT CONVENTION
15859470.5- Pending
INDIA
201717020515 - Pending
JAPAN
2017-525948 - Pending
USA
15/524,211 - Pending
METHODS AND COMPOSITIONS FOR MAINTAINING THE CONFIRMATIONS AND STRUCTURAL INTEGRITY OF BIOMOLECULES:
PATENT COOPERATION TREATY
PCT/US2017/042666- Pending